Chemomab Therapeutics Ltd (STU:2QV0)
€ 1.66 -0.01 (-0.6%) Market Cap: 31.31 Mil Enterprise Value: 13.16 Mil PE Ratio: 0 PB Ratio: 2.07 GF Score: 35/100

Chemomab Therapeutics Ltd at Aegis Virtual Conference Transcript

May 03, 2023 / 01:00PM GMT
Release Date Price: €1.28 (+0.79%)
Unidentified Participant

For everyone tuning in, we have Chemomab Therapeutics. They trade on the Nasdaq under the ticker CMMB. And when management is ready to get started, you guys can kick us off. Thank you.

Dale Pfost
Chemomab Therapeutics Ltd. - Chairman & CEO

Welcome. I'm Dale Pfost, CEO of Chemomab. And we are delighted to be presenting at the Ageas Conference today. I'm joined today by Adi Mor, our Co-Founder and CSO, Matt Frankel, our CMO, and Don Marvin, our EVP, COO, and CFO. Please refer to our forward-looking statements and risk factors, including those on file with the SEC.

Here's why we're so excited about Chemomab, in four key points we'll cover today. We have a unique dual activity target with disease-modifying potential addressing fundamental mechanisms of fibro-inflammatory disease. We've worked towards derisking our programs through 10 years of extensive preclinical studies reinforced by four completed clinical trials.

We expect to have two Phase 2 readouts in 2024, and we're addressing lethal diseases with high unmet need that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot